BioCentury
ARTICLE | Clinical News

Arvinas brings its first PROTAC to the clinic

March 29, 2019 6:24 PM UTC

Arvinas said it has started dosing metastatic castration-resistant prostate cancer patients in a Phase I trial of ARV-110, an oral androgen receptor-targeted PROTAC. Preliminary data are expected next half.

Arvinas Inc. (NASDAQ:ARVN) said it believes ARV-110 is the first therapy in its class to enter human trials. A PROTAC -- Proteolysis Targeting Chimera -- is a three-part compound consisting of one molecule that binds a target, a second molecule that mediates ubiquitination, and a chemical linker connecting the two (see "Down the Hatch")...

BCIQ Company Profiles

Arvinas Inc.

BCIQ Target Profiles

Androgen receptor